Global Cancer Monoclonal Antibodies Market Analysis 2021

The Global Cancer Monoclonal Antibodies Market is expected to reach $100.82 billion by 2027 growing at a CAGR of 13.31% from 2020 to 2027. Monoclonal antibodies (mAbs) are mono-specific antibody bodies including alike immune cells that are clones of a single parent cell and directed to precise cellular targets. Thus, Monoclonal antibodies are extremely customizable due to their specific nature and can play a vital role in removing cancerous cells while sparing the normal cells during the cancer treatment. The monoclonal antibodies are proved to be more effectual than chemotherapies and drugs for cancer treatment. Monoclonal antibodies could offer less toxic and efficient therapeutic substitutes to patients that have been developing in recent years. Monoclonal antibodies are used to treat an extensive array of diseases associated with autoimmune, inflammatory, and especially cancer. Factors such as increasing investment in research and development of genomic studies and technological advancements in genetic sequencing are driving the growth of the market. However, high developing cost is restraining the growth of the market. Based on the type of monoclonal antibody, the murine antibodies segment is going to have lucrative growth during the forecast period. The murine antibodies play a important role in developments of present-day antibody production procedures and evolving the potential usage of immunoglobins for several applications. The key vendors mentioned are Amgen Inc, Eli Lilly CoF, Hoffmann-La Roche AG, Merck & Co. Inc, Novartis AG, AbbVie Inc, Bayer AG, AstraZeneca plc, Biocon, Ltd, Bristol Myers Squibb Co, Daiichi Sankyo Company Ltd, F. Hoffmann-La Roche AG, Genmab A/S, GlaxoSmithKline plc, Innate Pharma S.A, Johnson & Johnson Services Inc, Oncologie, Inc, Pfizer Inc, Spectrum Pharmaceuticals Inc and Takeda Pharmaceutical Co. Ltd. Types Covered: • Naked • Conjugated Type of Monoclonal Antibodies Covered: • Chimeric Antibodies • Humanized Antibodies • Murine Antibodies Monoclonal Antibody Therapies Covered: • Bevacizumab (Avastin) • Cetuximab (Erbitux) • Panitumumab (Vectibix) • Rituximab (Rituxan) • Trastuzumab (Herceptin) Conjugate Cancer Therapies Covered: • Antibody-Directed Enzyme Prodrug Therapy (ADEPT) • Immunocytokines • Immunoliposome • Radioimmunotherapy Applications Covered: • Blood Cancer • Brain Cancer • Breast Cancer • Colorectal Cancer • Hodgkins and Non-Hodgkins lymphoma • Leukemia • Liver Cancer • Prostate Cancer • Glioma cancers • Bladder Cancer • Ovarian Cancer End Users Covered: • Hospitals and Clinics • Pharmacies • Research Laboratories Regions Covered: • North America • Europe • Asia Pacific • South America • Middle East & Africa Key Questions Answered in this Report: • How this market evolved since the year 2019 • Market size estimations, forecasts and CAGR for all the segments presented in the scope • Key Market Developments and financials of the key players • Opportunity Analysis for the new entrants • SWOT Analysis of the key players • Fastest growing markets analyzed during the forecast period

1 Market Synopsis

2 Research Outline
2.1 Research Snapshot
2.2 Research Methodology
2.3 Research Sources
2.3.1 Primary Research Sources
2.3.2 Secondary Research Sources

3 Market Dynamics
3.1 Drivers
3.2 Restraints

4 Market Environment
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Cancer Monoclonal Antibodies Market, By Type
5.1 Introduction
5.2 Naked
5.3 Conjugated

6 Global Cancer Monoclonal Antibodies Market, By Type of Monoclonal Antibody
6.1 Introduction
6.2 Chimeric Antibodies
6.3 Humanized Antibodies
6.4 Murine Antibodies

7 Global Cancer Monoclonal Antibodies Market, By Monoclonal Antibody Therapies
7.1 Introduction
7.2 Bevacizumab (Avastin)
7.3 Cetuximab (Erbitux)
7.4 Panitumumab (Vectibix)
7.5 Rituximab (Rituxan)
7.6 Trastuzumab (Herceptin)

8 Global Cancer Monoclonal Antibodies Market, By Conjugate Cancer Therapies
8.1 Introduction
8.2 Antibody-Directed Enzyme Prodrug Therapy (ADEPT)
8.3 Immunocytokines
8.4 Immunoliposome
8.5 Radioimmunotherapy

9 Global Cancer Monoclonal Antibodies Market, By Application
9.1 Introduction
9.2 Blood Cancer
9.3 Brain Cancer
9.4 Breast Cancer
9.5 Colorectal Cancer
9.6 Hodgkins and Non-Hodgkins lymphoma
9.7 Leukemia
9.8 Liver Cancer
9.9 Prostate Cancer
9.10 Glioma cancers
9.11 Bladder Cancer
9.11 Ovarian Cancer

10 Global Cancer Monoclonal Antibodies Market, By End User
10.1 Introduction
10.2 Hospitals and Clinics
10.3 Pharmacies
10.4 Research Laboratories

11 Global Cancer Monoclonal Antibodies Market, By Geography
11.1 Introduction
11.2 North America
11.3 Europe
11.4 Asia Pacific
11.5 South America
11.6 Middle East & Africa

12 Strategic Benchmarking

13 Vendors Landscape
13.1 Amgen Inc
13.2 Eli Lilly and Co
13.3 F. Hoffmann-La Roche AG
13.4 Merck & Co. Inc.
13.5 Novartis AG
13.6 AbbVie, Inc.
13.7 Bayer AG
13.8 AstraZeneca plc
13.9 Biocon, Ltd.
13.10 Bristol Myers Squibb Co.
13.11 Daiichi Sankyo Company Ltd
13.12 F. Hoffmann-La Roche AG
13.13 Genmab A/S
13.14 GlaxoSmithKline plc
13.15 Innate Pharma S.A.
13.16 Johnson & Johnson Services Inc.
13.17 Oncologie, Inc.
13.18 Pfizer Inc.
13.19 Spectrum Pharmaceuticals Inc
13.20 Takeda Pharmaceutical Co. Ltd

List of Data Tables
1 Global Cancer Monoclonal Antibodies Market Outlook, By Region (2019-2027) ($MN)
2 Global Cancer Monoclonal Antibodies Market Outlook, By Type (2019-2027) ($MN)
3 Global Cancer Monoclonal Antibodies Market Outlook, By Naked (2019-2027) ($MN)
4 Global Cancer Monoclonal Antibodies Market Outlook, By Conjugated (2019-2027) ($MN)
5 Global Cancer Monoclonal Antibodies Market Outlook, By Type of Monoclonal Antibody (2019-2027) ($MN)
6 Global Cancer Monoclonal Antibodies Market Outlook, By Chimeric Antibodies (2019-2027) ($MN)
7 Global Cancer Monoclonal Antibodies Market Outlook, By Humanized Antibodies (2019-2027) ($MN)
8 Global Cancer Monoclonal Antibodies Market Outlook, By Murine Antibodies (2019-2027) ($MN)
9 Global Cancer Monoclonal Antibodies Market Outlook, By Monoclonal Antibody Therapies (2019-2027) ($MN)
10 Global Cancer Monoclonal Antibodies Market Outlook, By Bevacizumab (Avastin) (2019-2027) ($MN)
11 Global Cancer Monoclonal Antibodies Market Outlook, By Cetuximab (Erbitux) (2019-2027) ($MN)
12 Global Cancer Monoclonal Antibodies Market Outlook, By Panitumumab (Vectibix) (2019-2027) ($MN)
13 Global Cancer Monoclonal Antibodies Market Outlook, By Rituximab (Rituxan) (2019-2027) ($MN)
14 Global Cancer Monoclonal Antibodies Market Outlook, By Trastuzumab (Herceptin) (2019-2027) ($MN)
15 Global Cancer Monoclonal Antibodies Market Outlook, By Conjugate Cancer Therapies (2019-2027) ($MN)
16 Global Cancer Monoclonal Antibodies Market Outlook, By Antibody-Directed Enzyme Prodrug Therapy (ADEPT) (2019-2027) ($MN)
17 Global Cancer Monoclonal Antibodies Market Outlook, By Immunocytokines (2019-2027) ($MN)
18 Global Cancer Monoclonal Antibodies Market Outlook, By Immunoliposome (2019-2027) ($MN)
19 Global Cancer Monoclonal Antibodies Market Outlook, By Radioimmunotherapy (2019-2027) ($MN)
20 Global Cancer Monoclonal Antibodies Market Outlook, By Application (2019-2027) ($MN)
21 Global Cancer Monoclonal Antibodies Market Outlook, By Blood Cancer (2019-2027) ($MN)
22 Global Cancer Monoclonal Antibodies Market Outlook, By Brain Cancer (2019-2027) ($MN)
23 Global Cancer Monoclonal Antibodies Market Outlook, By Breast Cancer (2019-2027) ($MN)
24 Global Cancer Monoclonal Antibodies Market Outlook, By Colorectal Cancer (2019-2027) ($MN)
25 Global Cancer Monoclonal Antibodies Market Outlook, By Hodgkins and Non-Hodgkins lymphoma (2019-2027) ($MN)
26 Global Cancer Monoclonal Antibodies Market Outlook, By Leukemia (2019-2027) ($MN)
27 Global Cancer Monoclonal Antibodies Market Outlook, By Liver Cancer (2019-2027) ($MN)
28 Global Cancer Monoclonal Antibodies Market Outlook, By Prostate Cancer (2019-2027) ($MN)
29 Global Cancer Monoclonal Antibodies Market Outlook, By Glioma Cancer (2019-2027) ($MN)
30 Global Cancer Monoclonal Antibodies Market Outlook, By Bladder Cancer (2019-2027) ($MN)
31 Global Cancer Monoclonal Antibodies Market Outlook, By Ovarian Cancer (2019-2027) ($MN)
32 Global Cancer Monoclonal Antibodies Market Outlook, By End User (2019-2027) ($MN)
33 Global Cancer Monoclonal Antibodies Market Outlook, By Hospitals and Clinics (2019-2027) ($MN)
34 Global Cancer Monoclonal Antibodies Market Outlook, By Pharmacies (2019-2027) ($MN)
35 Global Cancer Monoclonal Antibodies Market Outlook, By Research Laboratories (2019-2027) ($MN)
36 North America Cancer Monoclonal Antibodies Market Outlook, By Type (2019-2027) ($MN)
37 North America Cancer Monoclonal Antibodies Market Outlook, By Type of Monoclonal Antibody (2019-2027) ($MN)
38 North America Cancer Monoclonal Antibodies Market Outlook, By Conjugate Cancer Therapies (2019-2027) ($MN)
39 North America Cancer Monoclonal Antibodies Market Outlook, By Application (2019-2027) ($MN)
40 North America Cancer Monoclonal Antibodies Market Outlook, By End User (2019-2027) ($MN)
41 Europe Cancer Monoclonal Antibodies Market Outlook, By Type (2019-2027) ($MN)
42 Europe Cancer Monoclonal Antibodies Market Outlook, By Type of Monoclonal Antibody (2019-2027) ($MN)
43 Europe Cancer Monoclonal Antibodies Market Outlook, By Conjugate Cancer Therapies (2019-2027) ($MN)
44 Europe Cancer Monoclonal Antibodies Market Outlook, By Application (2019-2027) ($MN)
45 Europe Cancer Monoclonal Antibodies Market Outlook, By End User (2019-2027) ($MN)
46 Asia Pacific Cancer Monoclonal Antibodies Market Outlook, By Type (2019-2027) ($MN)
47 Asia Pacific Cancer Monoclonal Antibodies Market Outlook, By Type of Monoclonal Antibody (2019-2027) ($MN)
48 Asia Pacific Cancer Monoclonal Antibodies Market Outlook, By Conjugate Cancer Therapies (2019-2027) ($MN)
49 Asia Pacific Cancer Monoclonal Antibodies Market Outlook, By Application (2019-2027) ($MN)
50 Asia Pacific Cancer Monoclonal Antibodies Market Outlook, By End User (2019-2027) ($MN)
51 South America Cancer Monoclonal Antibodies Market Outlook, By Type (2019-2027) ($MN)
52 South America Cancer Monoclonal Antibodies Market Outlook, By Type of Monoclonal Antibody (2019-2027) ($MN)
53 South America Cancer Monoclonal Antibodies Market Outlook, By Conjugate Cancer Therapies (2019-2027) ($MN)
54 South America Cancer Monoclonal Antibodies Market Outlook, By Application (2019-2027) ($MN)
55 South America Cancer Monoclonal Antibodies Market Outlook, By End User (2019-2027) ($MN)
56 Middle East & Africa Cancer Monoclonal Antibodies Market Outlook, By Type (2019-2027) ($MN)
57 Middle East & Africa Cancer Monoclonal Antibodies Market Outlook, By Type of Monoclonal Antibody (2019-2027) ($MN)
58 Middle East & Africa Cancer Monoclonal Antibodies Market Outlook, By Conjugate Cancer Therapies (2019-2027) ($MN)
59 Middle East & Africa Cancer Monoclonal Antibodies Market Outlook, By Application (2019-2027) ($MN)
60 Middle East & Africa Cancer Monoclonal Antibodies Market Outlook, By End User (2019-2027) ($MN)